123 related articles for article (PubMed ID: 4078594)
1. Optimization of an immunotherapeutic protocol with poly(I,C)-LC.
Talmadge JE; Hartmann D
J Biol Response Mod; 1985 Oct; 4(5):484-9. PubMed ID: 4078594
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
[TBL] [Abstract][Full Text] [Related]
3. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
Talmadge JE; Chirigos MA
Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016
[No Abstract] [Full Text] [Related]
4. The effect of interferon on rabies infection of animals.
Baer GM
Tex Rep Biol Med; 1981-1982; 41():526-31. PubMed ID: 6189218
[No Abstract] [Full Text] [Related]
5. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.
Theriault RL; Hortobagyi GN; Buzdar AU; Levy HB; Hersh EM
Cancer Treat Rep; 1986 Nov; 70(11):1341-2. PubMed ID: 3768878
[No Abstract] [Full Text] [Related]
6. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
7. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
[No Abstract] [Full Text] [Related]
9. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
Leventhal BG; Kashima H; Levine AS; Levy HB
J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
[No Abstract] [Full Text] [Related]
11. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
12. A preliminary trial of poly(I,C)-LC in multiple sclerosis.
McFarlin DE; Bever CT; Salazar AM; Levy HB
J Biol Response Mod; 1985 Oct; 4(5):544-8. PubMed ID: 2416885
[TBL] [Abstract][Full Text] [Related]
13. Phase I trials of poly(I,C) complexes in advanced cancer.
Krown SE; Kerr D; Stewart WE; Field AK; Oettgen HF
J Biol Response Mod; 1985 Dec; 4(6):640-9. PubMed ID: 2418162
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of poly(I,C)-LC in cancer patients.
Maluish AE; Reid JW; Crisp EA; Overton WR; Levy H; Foon KA; Herberman RB
J Biol Response Mod; 1985 Dec; 4(6):656-63. PubMed ID: 4087034
[TBL] [Abstract][Full Text] [Related]
15. [Effect of a modified polyinosinic acid--polycytidylic acid complex against herpes simplex keratitis in monkeys (author's transl)].
Teranishi H
Nippon Ganka Gakkai Zasshi; 1980 Sep; 84(9):1198-204. PubMed ID: 7223554
[No Abstract] [Full Text] [Related]
16. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
17. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma.
Durie BG; Levy HB; Voakes J; Jett JR; Levine AS
J Biol Response Mod; 1985 Oct; 4(5):518-24. PubMed ID: 3935757
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol
Kumaki Y; Salazar AM; Wandersee MK; Barnard DL
Antiviral Res; 2017 Mar; 139():1-12. PubMed ID: 27956136
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.
Wong JP; Saravolac EG; Sabuda D; Levy HB; Kende M
Antimicrob Agents Chemother; 1995 Nov; 39(11):2574-6. PubMed ID: 8585749
[TBL] [Abstract][Full Text] [Related]
20. A phase I evaluation of poly(I,C)-LC in cancer patients.
Stevenson HC; Abrams PG; Schoenberger CS; Smalley RB; Herberman RB; Foon KA
J Biol Response Mod; 1985 Dec; 4(6):650-5. PubMed ID: 2418163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
